Does the media prefer ENLV or FATE?

In the previous week, Enlivex Therapeutics had 6 more articles in the media than Fate Therapeutics. MarketBeat recorded 10 mentions for Enlivex Therapeutics and 4 mentions for Fate Therapeutics. Enlivex Therapeutics' average media sentiment score of 0.62 beat Fate Therapeutics' score of 0.39 indicating that Enlivex Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enlivex Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Fate Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, ENLV or IMRX?

Immuneering is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enlivex Therapeutics N/A N/A $1.24B -$8.25 N/A Immuneering N/A N/A -$56.03M -$1.04 N/A

Is ENLV or IMRX more profitable?

Enlivex Therapeutics' return on equity of 248.08% beat Immuneering's return on equity. Company Net Margins Return on Equity Return on Assets Enlivex Therapeutics N/A 248.08% 206.39% Immuneering N/A -27.15% -25.75%

Does the media prefer ENLV or IMRX?

In the previous week, Immuneering had 10 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 20 mentions for Immuneering and 10 mentions for Enlivex Therapeutics. Immuneering's average media sentiment score of 0.83 beat Enlivex Therapeutics' score of 0.62 indicating that Immuneering is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enlivex Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Immuneering 5 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor IRD or ENLV?

In the previous week, Opus Genetics and Opus Genetics both had 10 articles in the media. Enlivex Therapeutics' average media sentiment score of 0.62 beat Opus Genetics' score of 0.12 indicating that Enlivex Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Opus Genetics 1 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Enlivex Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ENLV or BCYC?

In the previous week, Enlivex Therapeutics had 5 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 10 mentions for Enlivex Therapeutics and 5 mentions for Bicycle Therapeutics. Enlivex Therapeutics' average media sentiment score of 0.62 beat Bicycle Therapeutics' score of 0.51 indicating that Enlivex Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enlivex Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Bicycle Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, ELDN or ENLV?

Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eledon Pharmaceuticals N/A N/A -$45.62M -$0.77 N/A Enlivex Therapeutics N/A N/A $1.24B -$8.25 N/A

Is ELDN or ENLV more profitable?

Enlivex Therapeutics' return on equity of 248.08% beat Eledon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Eledon Pharmaceuticals N/A -116.97% -41.91% Enlivex Therapeutics N/A 248.08% 206.39%

Does the media prefer ELDN or ENLV?

In the previous week, Enlivex Therapeutics had 9 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 10 mentions for Enlivex Therapeutics and 1 mentions for Eledon Pharmaceuticals. Enlivex Therapeutics' average media sentiment score of 0.62 beat Eledon Pharmaceuticals' score of 0.00 indicating that Enlivex Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eledon Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Enlivex Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Enlivex Therapeutics (ENLV) Competitors

$2.10 +0.02 (+0.72%)

As of 12:00 PM Eastern

Compare

ENLV vs. FATE, IMRX, IRD, BCYC, and ELDN

Should you buy Enlivex Therapeutics stock or one of its competitors? MarketBeat compares Enlivex Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Enlivex Therapeutics include Fate Therapeutics (FATE), Immuneering (IMRX), Opus Genetics (IRD), Bicycle Therapeutics (BCYC), and Eledon Pharmaceuticals (ELDN).

How does Enlivex Therapeutics compare to Fate Therapeutics?

Enlivex Therapeutics (NASDAQ:ENLV) and Fate Therapeutics (NASDAQ:FATE) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends and valuation.

In the previous week, Enlivex Therapeutics had 6 more articles in the media than Fate Therapeutics. MarketBeat recorded 10 mentions for Enlivex Therapeutics and 4 mentions for Fate Therapeutics. Enlivex Therapeutics' average media sentiment score of 0.62 beat Fate Therapeutics' score of 0.39 indicating that Enlivex Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enlivex Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Fate Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Enlivex Therapeutics currently has a consensus target price of $247.50, indicating a potential upside of 11,713.84%. Fate Therapeutics has a consensus target price of $5.13, indicating a potential upside of 84.68%. Given Enlivex Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Enlivex Therapeutics is more favorable than Fate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Enlivex Therapeutics has higher earnings, but lower revenue than Fate Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enlivex Therapeutics	N/A	N/A	$1.24B	-$8.25	N/A
Fate Therapeutics	$6.65M	48.64	-$136.32M	-$1.09	N/A

Enlivex Therapeutics has a net margin of 0.00% compared to Fate Therapeutics' net margin of -2,056.79%. Enlivex Therapeutics' return on equity of 248.08% beat Fate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enlivex Therapeutics	N/A	248.08%	206.39%
Fate Therapeutics	-2,056.79%	-58.89%	-39.39%

1.0% of Enlivex Therapeutics shares are held by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are held by institutional investors. 12.3% of Enlivex Therapeutics shares are held by company insiders. Comparatively, 4.7% of Fate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Enlivex Therapeutics has a beta of 1.6, suggesting that its stock price is 60% more volatile than the broader market. Comparatively, Fate Therapeutics has a beta of 2.52, suggesting that its stock price is 152% more volatile than the broader market.

Summary

Enlivex Therapeutics beats Fate Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Enlivex Therapeutics compare to Immuneering?

Enlivex Therapeutics (NASDAQ:ENLV) and Immuneering (NASDAQ:IMRX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

Enlivex Therapeutics has a beta of 1.6, suggesting that its stock price is 60% more volatile than the broader market. Comparatively, Immuneering has a beta of 0.43, suggesting that its stock price is 57% less volatile than the broader market.

Immuneering is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enlivex Therapeutics	N/A	N/A	$1.24B	-$8.25	N/A
Immuneering	N/A	N/A	-$56.03M	-$1.04	N/A

In the previous week, Immuneering had 10 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 20 mentions for Immuneering and 10 mentions for Enlivex Therapeutics. Immuneering's average media sentiment score of 0.83 beat Enlivex Therapeutics' score of 0.62 indicating that Immuneering is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enlivex Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Immuneering	5 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

1.0% of Enlivex Therapeutics shares are held by institutional investors. Comparatively, 67.7% of Immuneering shares are held by institutional investors. 12.3% of Enlivex Therapeutics shares are held by company insiders. Comparatively, 14.9% of Immuneering shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Enlivex Therapeutics' return on equity of 248.08% beat Immuneering's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enlivex Therapeutics	N/A	248.08%	206.39%
Immuneering	N/A	-27.15%	-25.75%

Enlivex Therapeutics currently has a consensus price target of $247.50, suggesting a potential upside of 11,713.84%. Immuneering has a consensus price target of $17.50, suggesting a potential upside of 279.20%. Given Enlivex Therapeutics' higher possible upside, equities research analysts plainly believe Enlivex Therapeutics is more favorable than Immuneering.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Immuneering	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Immuneering beats Enlivex Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Enlivex Therapeutics compare to Opus Genetics?

Opus Genetics (NASDAQ:IRD) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and media sentiment.

In the previous week, Opus Genetics and Opus Genetics both had 10 articles in the media. Enlivex Therapeutics' average media sentiment score of 0.62 beat Opus Genetics' score of 0.12 indicating that Enlivex Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Opus Genetics	1 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Enlivex Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Enlivex Therapeutics has lower revenue, but higher earnings than Opus Genetics. Opus Genetics is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Opus Genetics	$14.20M	21.78	-$49.59M	-$1.35	N/A
Enlivex Therapeutics	N/A	N/A	$1.24B	-$8.25	N/A

Opus Genetics presently has a consensus target price of $10.69, indicating a potential upside of 185.51%. Enlivex Therapeutics has a consensus target price of $247.50, indicating a potential upside of 11,713.84%. Given Enlivex Therapeutics' higher possible upside, analysts clearly believe Enlivex Therapeutics is more favorable than Opus Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opus Genetics	2 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.83
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

15.0% of Opus Genetics shares are held by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are held by institutional investors. 11.7% of Opus Genetics shares are held by company insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Enlivex Therapeutics has a net margin of 0.00% compared to Opus Genetics' net margin of -1,091.82%. Enlivex Therapeutics' return on equity of 248.08% beat Opus Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Opus Genetics	-1,091.82%	-338.88%	-150.13%
Enlivex Therapeutics	N/A	248.08%	206.39%

Opus Genetics has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market. Comparatively, Enlivex Therapeutics has a beta of 1.6, indicating that its share price is 60% more volatile than the broader market.

Summary

Enlivex Therapeutics beats Opus Genetics on 9 of the 14 factors compared between the two stocks.

How does Enlivex Therapeutics compare to Bicycle Therapeutics?

Enlivex Therapeutics (NASDAQ:ENLV) and Bicycle Therapeutics (NASDAQ:BCYC) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, media sentiment, dividends, profitability, valuation and risk.

Enlivex Therapeutics currently has a consensus target price of $247.50, indicating a potential upside of 11,713.84%. Bicycle Therapeutics has a consensus target price of $13.86, indicating a potential upside of 235.12%. Given Enlivex Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Enlivex Therapeutics is more favorable than Bicycle Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

In the previous week, Enlivex Therapeutics had 5 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 10 mentions for Enlivex Therapeutics and 5 mentions for Bicycle Therapeutics. Enlivex Therapeutics' average media sentiment score of 0.62 beat Bicycle Therapeutics' score of 0.51 indicating that Enlivex Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enlivex Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Bicycle Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Enlivex Therapeutics has higher earnings, but lower revenue than Bicycle Therapeutics. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enlivex Therapeutics	N/A	N/A	$1.24B	-$8.25	N/A
Bicycle Therapeutics	$72.86M	3.96	-$218.96M	-$2.73	N/A

Enlivex Therapeutics has a beta of 1.6, suggesting that its stock price is 60% more volatile than the broader market. Comparatively, Bicycle Therapeutics has a beta of 1.55, suggesting that its stock price is 55% more volatile than the broader market.

Enlivex Therapeutics has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -311.11%. Enlivex Therapeutics' return on equity of 248.08% beat Bicycle Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enlivex Therapeutics	N/A	248.08%	206.39%
Bicycle Therapeutics	-311.11%	-33.22%	-27.79%

1.0% of Enlivex Therapeutics shares are held by institutional investors. Comparatively, 86.2% of Bicycle Therapeutics shares are held by institutional investors. 12.3% of Enlivex Therapeutics shares are held by insiders. Comparatively, 22.0% of Bicycle Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Enlivex Therapeutics beats Bicycle Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Enlivex Therapeutics compare to Eledon Pharmaceuticals?

Eledon Pharmaceuticals (NASDAQ:ELDN) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings, media sentiment and risk.

Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.77	N/A
Enlivex Therapeutics	N/A	N/A	$1.24B	-$8.25	N/A

56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are owned by institutional investors. 9.6% of Eledon Pharmaceuticals shares are owned by company insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Enlivex Therapeutics' return on equity of 248.08% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eledon Pharmaceuticals	N/A	-116.97%	-41.91%
Enlivex Therapeutics	N/A	248.08%	206.39%

In the previous week, Enlivex Therapeutics had 9 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 10 mentions for Enlivex Therapeutics and 1 mentions for Eledon Pharmaceuticals. Enlivex Therapeutics' average media sentiment score of 0.62 beat Eledon Pharmaceuticals' score of 0.00 indicating that Enlivex Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eledon Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Enlivex Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Eledon Pharmaceuticals has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market. Comparatively, Enlivex Therapeutics has a beta of 1.6, suggesting that its stock price is 60% more volatile than the broader market.

Eledon Pharmaceuticals presently has a consensus target price of $9.67, suggesting a potential upside of 157.43%. Enlivex Therapeutics has a consensus target price of $247.50, suggesting a potential upside of 11,713.84%. Given Enlivex Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Enlivex Therapeutics is more favorable than Eledon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Enlivex Therapeutics beats Eledon Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

Get Enlivex Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENLV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENLV vs. The Competition

Export

Metric	Enlivex Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$35.26M	$3.71B	$7.03B	$12.96B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-0.25	9.06	269.93	24.86
Price / Sales	N/A	1,267.27	650.62	108.28
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	0.02	17.63	11.25	6.44
Net Income	$1.24B	-$13.25M	$3.45B	$347.39M
7 Day Performance	-3.46%	5.49%	3.67%	2.69%
1 Month Performance	-69.46%	-1.66%	-0.49%	-0.90%
1 Year Performance	-90.23%	61.27%	77.44%	23.51%

Enlivex Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENLV Enlivex Therapeutics	4.0452 of 5 stars	$2.10 +0.7%	$247.50 +11,713.8%	-90.3%	$35.26M	N/A	N/A	70	Gap Down
FATE Fate Therapeutics	3.3395 of 5 stars	$2.32 -4.5%	$5.13 +120.9%	+203.9%	$283.24M	$6.65M	N/A	550	News Coverage Upcoming Earnings
IMRX Immuneering	3.3647 of 5 stars	$4.24 -2.8%	$17.57 +314.4%	+38.8%	$282.08M	N/A	N/A	60	News Coverage Earnings Report Analyst Revision
IRD Opus Genetics	2.7028 of 5 stars	$3.41 +1.8%	$10.77 +215.8%	+242.1%	$276.60M	$14.20M	N/A	14	Earnings Report Analyst Forecast
BCYC Bicycle Therapeutics	3.1922 of 5 stars	$3.94 -0.3%	$14.00 +255.3%	-45.5%	$275.75M	$72.86M	N/A	240

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENLV) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Enlivex Therapeutics (ENLV) Competitors

ENLV vs. FATE, IMRX, IRD, BCYC, and ELDN

How does Enlivex Therapeutics compare to Fate Therapeutics?

Summary

How does Enlivex Therapeutics compare to Immuneering?

Summary

How does Enlivex Therapeutics compare to Opus Genetics?

Summary

How does Enlivex Therapeutics compare to Bicycle Therapeutics?

Summary

How does Enlivex Therapeutics compare to Eledon Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENLV vs. The Competition

Enlivex Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Enlivex Therapeutics (ENLV) Competitors

ENLV vs. FATE, IMRX, IRD, BCYC, and ELDN

How does Enlivex Therapeutics compare to Fate Therapeutics?

Does the media prefer ENLV or FATE?

Do analysts rate ENLV or FATE?

Which has higher earnings & valuation, ENLV or FATE?

Is ENLV or FATE more profitable?

Do insiders & institutionals believe in ENLV or FATE?

Which has more risk & volatility, ENLV or FATE?

Summary

How does Enlivex Therapeutics compare to Immuneering?

Which has more risk & volatility, ENLV or IMRX?

Which has preferable valuation and earnings, ENLV or IMRX?

Does the media prefer ENLV or IMRX?

Do institutionals and insiders have more ownership in ENLV or IMRX?

Is ENLV or IMRX more profitable?

Do analysts recommend ENLV or IMRX?

Summary

How does Enlivex Therapeutics compare to Opus Genetics?

Does the media favor IRD or ENLV?

Which has better valuation & earnings, IRD or ENLV?

Do analysts rate IRD or ENLV?

Do institutionals & insiders believe in IRD or ENLV?

Is IRD or ENLV more profitable?

Which has more volatility and risk, IRD or ENLV?

Summary

How does Enlivex Therapeutics compare to Bicycle Therapeutics?

Do analysts recommend ENLV or BCYC?

Does the media refer more to ENLV or BCYC?

Which has stronger earnings & valuation, ENLV or BCYC?

Which has more risk & volatility, ENLV or BCYC?

Is ENLV or BCYC more profitable?

Do insiders & institutionals believe in ENLV or BCYC?

Summary

How does Enlivex Therapeutics compare to Eledon Pharmaceuticals?

Which has preferable valuation & earnings, ELDN or ENLV?

Do institutionals & insiders have more ownership in ELDN or ENLV?

Is ELDN or ENLV more profitable?

Does the media prefer ELDN or ENLV?

Which has more risk & volatility, ELDN or ENLV?

Do analysts rate ELDN or ENLV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENLV vs. The Competition

Enlivex Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools